Clinical Cancer Research CR Balducci Advances in Breast Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sauter, E. R.
Right arrow Articles by Ridge, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sauter, E. R.
Right arrow Articles by Ridge, J. A.
Clinical Cancer Research Vol. 6, 654-660, February 2000
© 2000 American Association for Cancer Research

Experimental Therapeutics, Preclinical Pharmacology

Prolonged Response to Antisense Cyclin D1 in a Human Squamous Cancer Xenograft Model1

Edward R. Sauter2, Meenhard Herlyn, Shao-Chen Liu, Samuel Litwin and John A. Ridge

Department of Surgery, Thomas Jefferson University [E. R. S.], Division of Population Science [S. C. L., S. L.], and the Department of Surgery [J. A. R.], Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, and the Department of Molecular and Cellular Biology, The Wistar Institute, Philadelphia, Pennsylvania 19104 [E. R. S., M. H.]

Local recurrence of squamous cell cancer (SCC) causes high morbidity and is often readily accessible, making such patients potential candidates for gene therapy. Cyclin D1 (CD1), critical in the G1-S transition in the cell cycle, is amplified in 20–50% and overexpressed in up to 80% of head and neck SCC. Our earlier studies indicated that CD1 expression increased with progression from low grade to high grade dysplasia, and that treatment of established tumors with antisense cyclin D1 (AS-cyclin D1) led to tumor regression during a one week evaluation period. We hypothesized that: 1) CD1 expression increases with disease progression to advanced SCC, and 2) AS-cyclin D1 therapy would lead to prolonged tumor regression in a xenograft model of human SCC. CD1 expression, evaluated by immunostain in 30 stage III/IV head and neck SCC, increased in the basal layer from normal-dysplasia (P = 0.06) and from dysplasia-carcinoma (P = 0.004). In the germinative layer CD1 expression increased from dysplasia-carcinoma (P = 0.002) but not from normal-dysplasia. Western blotting of eight SCC and two transformed keratinocyte cell lines demonstrated CD1 overexpression in 8/10 (80%) lines. An 11th cell line (A431) had previously been shown to overexpress cyclin D1. 8/9 (89%) cell lines overexpressing CD1 formed tumors in immunodeficient mice, whereas 0/2 cell lines without CD1 overexpression formed a tumor. Three established SCCs, one fast growing, one with moderate growth rate (with CD1 overexpression) and one slow growing (without increased CD1), shrank significantly for 2–4 weeks after AS-cyclin D1 treatment, while tumors transduced with control vector grew. Cyclin D1 expression increases in frequency with disease progression, and antisense cyclin D1 was effective in a xenograft model of human cancer, independent of tumor growth rate.




This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
S. Wei, H.-C. Yang, H.-C. Chuang, J. Yang, S. K. Kulp, P.-J. Lu, M.-D. Lai, and C.-S. Chen
A Novel Mechanism by Which Thiazolidinediones Facilitate the Proteasomal Degradation of Cyclin D1 in Cancer Cells
J. Biol. Chem., September 26, 2008; 283(39): 26759 - 26770.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. H. Kalish, R. A. Kwong, I. E. Cole, R. M. Gallagher, R. L. Sutherland, and E. A. Musgrove
Deregulated Cyclin D1 Expression Is Associated with Decreased Efficacy of the Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Gefitinib in Head and Neck Squamous Cell Carcinoma Cell Lines
Clin. Cancer Res., November 15, 2004; 10(22): 7764 - 7774.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. R. Sauter, U.-C. Yeo, A. von Stemm, W. Zhu, S. Litwin, D. S. Tichansky, G. Pistritto, M. Nesbit, D. Pinkel, M. Herlyn, et al.
Cyclin D1 Is a Candidate Oncogene in Cutaneous Melanoma
Cancer Res., June 1, 2002; 62(11): 3200 - 3206.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
M. E. Laurance, D. B. Starr, E. F. Michelotti, E. Cheung, C. Gonzalez, A. W. Tam, J. Deikman, C. A. Edwards, and A. J. Bardwell
Specific down-regulation of an engineered human cyclin D1 promoter by a novel DNA-binding ligand in intact cells
Nucleic Acids Res., February 1, 2001; 29(3): 652 - 661.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2000 by the American Association for Cancer Research.